Bernhard Moser

This inventor holds 8 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Theodor-Kocher Institute, University College Cardiff Consultants Limited, Millennium Pharmaceuticals Limited. Active years: 2000-2012.

USPTO Granted Patents = 8 (Patent Applications = 1)

% Patents Active = 62.5

EPO Patents = 1

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 67(Granted Patents)

Location History:

Stettlen, CH (2000 - 2006)
Utzenstorf, CH (2008 - 2012)

Company Filing History:

5 out of 5

Theodor-Kocher Institute

patents

2 out of 136

University College Cardiff Consultants Limited

patents

1 out of 854

Millennium Pharmaceuticals Limited

patents

4. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2012

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8338173 - Preparation of antigen-presenting human γδ T cells and use in immunotherapy (2012-12-25),

2. 8153426 - Preparation of antigen-presenting human gamma-delta T cells and use in immunotherapy (2012-04-10),

3. 7407655 - Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody (2008-08-05),

4. 7029862 - Method for identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 (2006-04-18),

5. 6833439 - IP-10/MIG receptor designated CXCR3, nucleic acids and methods of use therefor (2004-12-21),

6. 6686175 - IP-10/MIG receptor designated CXCR3, nucleic acids, and methods of use therefor (2004-02-03),

7. 6184358 - IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor (2001-02-06),

8. 6140064 - Method of detecting or identifying ligands, inhibitors or promoters of (2000-10-31),

Title: Bernhard Moser: Innovator in Immunotherapy

Introduction

Bernhard Moser is a prominent inventor based in Utzenstorf, Switzerland. He has made significant contributions to the field of immunotherapy, particularly through his innovative methods involving human gamma-delta T cells. With a total of 8 patents to his name, Moser's work is paving the way for advancements in cancer treatment and infectious disease management.

Latest Patents

Moser's latest patents focus on the preparation of antigen-presenting human gamma-delta T cells and their use in immunotherapy. One of his notable inventions demonstrates the ability of activated gamma-delta T cells to cross-present exogenous antigens to CD8 alpha-beta T cells. This process, previously thought to be primarily mediated by dendritic cells, opens new avenues for treatment. His methods provide a way to prepare peptide-specific effector T cells and utilize them in treating tumors or chronic infectious diseases. The efficiency of these gamma-delta T cells in processing antigens and inducing strong immune responses highlights their potential in vaccine development and diagnostics.

Career Highlights

Throughout his career, Moser has worked with esteemed institutions such as the Theodor Kocher Institute and University College Cardiff Consultants Limited. His research has significantly impacted the understanding of immune responses and the development of therapeutic strategies.

Collaborations

Moser has collaborated with notable colleagues, including Marcel Loetscher and Shixin Qin. These partnerships have further enriched his research and contributed to the advancement of immunotherapy techniques.

Conclusion

Bernhard Moser's innovative work in the field of immunotherapy exemplifies the potential of gamma-delta T cells in medical treatments. His contributions are vital for the future of cancer therapy and infectious disease management.